Fitterfly’s Reimagining Diabetes Care Report 2024: Growing Adoption and Better Health Outcomes with Digital Therapeutics

Mumbai (Maharashtra) [India], January 17: As India grapples with a diabetes epidemic, Fitterfly, a leading ISO-13485 certified digital therapeutics company with clinically-proven programs, releases its comprehensive report, ‘Reimagining Diabetes Care 2024’. This study showcases the data from the Fitterfly Diabetes prime program across 2023 and the critical role digital therapies now play in empowering people to effectively manage diabetes.